Table 4.
Ten‐Year Risk of Adverse Events Per 1000 Patient‐Years by Postevent Mean LDL‐C
| Postevent mean LDL‐C | ||
|---|---|---|
| <1.80 mmol/L | ≥1.80 mmol/L | |
| All recurrent stroke | ||
| No. | 279 | 625 |
| All subjects | 1.42 (0.99–2.05) | 2.42 (2.00–2.91) |
| LAD+ | 1.29 (0.75–2.22) | 2.35 (1.81–3.05) |
| LAD− | 1.55 (0.95–2.54) | 2.49 (1.91–3.25) |
| Recurrent ischemic stroke | ||
| No. | 281 | 623 |
| All subjects | 1.27 (0.86–1.86) | 1.86 (1.51–2.30) |
| LAD+ | 1.17 (0.67–2.07) | 1.84 (1.37–2.47) |
| LAD− | 1.36 (0.80–2.29) | 1.90 (1.40–2.57) |
| Intracerebral hemorrhage | ||
| No. | 284 | 620 |
| All subjects | 0.14 (0.04–0.43) | 0.50 (0.33–0.74) |
| LAD+ | 0.09 (0.01–0.64) | 0.48 (0.27–0.84) |
| LAD− | 0.19 (0.05–0.75) | 0.52 (0.29–0.91) |
| Major adverse cardiovascular event | ||
| No. | 270 | 634 |
| All subjects | 2.98 (2.29–3.87) | 4.38 (3.80–5.05) |
| LAD+ | 3.50 (2.47–4.95) | 4.76 (3.94–5.76) |
| LAD− | 2.49 (1.67–3.71) | 3.98 (3.21–4.93) |
| All‐cause mortality | ||
| No. | 286 | 618 |
| All subjects | 2.89 (2.26–3.70) | 3.39 (2.91–3.95) |
| LAD+ | 3.43 (2.50–4.72) | 4.23 (3.50–5.11) |
| LAD– | 2.33 (1.57–3.45) | 2.49 (1.93–3.22) |
LAD+ indicates with significant large‐artery atherosclerosis; LAD−, without significant large‐artery atherosclerosis; and LDL‐C, low‐density lipoprotein cholesterol.